3,3-二甲基-1-苯基甲基-4-羟基哌啶 | 324769-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3,3-二甲基-1-苯基甲基-4-羟基哌啶
• 英文名称: (rac)-1-Benzyl-3,3-dimethyl-piperidin-4-ol
• 英文别名: 1-benzyl-3,3-dimethyl-4-hydroxypiperidine；1-Benzyl-3,3-dimethylpiperidin-4-OL
• CAS: 324769-02-0
• 化学式: C₁₄H₂₁NO
• mdl: MFCD11977346
• 分子量: 219.327
• InChiKey: ZOTKRTQMBDUPHD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3,3-二甲基-1-苯基甲基-4-羟基哌啶 在 palladium 10% on activated carbon 氢气 、 二甲基亚砜 、 三氟乙酸酐 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 甲醇 、 正庚烷 、 二氯甲烷 为溶剂， -78.0~20.0 ℃ 、446.08 kPa 条件下， 反应 23.34h， 生成 tert-butyl 3,3-dimethyl-4-(((trifluoromethyl)sulfonyl)oxy)-3,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  SEROTONERGIC BENZOFURANS

  摘要：

  公开号：

  EP1204659B1
• 作为产物：
  描述：

  1-苄基-3,3-二甲基哌啶-2,4-二酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 19.0h， 以88%的产率得到3,3-二甲基-1-苯基甲基-4-羟基哌啶
  参考文献：
  名称：

  SEROTONERGIC BENZOFURANS

  摘要：

  公开号：

  EP1204659B1

文献信息

• Novel diazepan derivatives
  申请人：Aebi Johannes

  公开号：US20070249589A1

  公开（公告）日：2007-10-25

  The invention is concerned with novel diazepan derivatives of formula (I) wherein A, X, R 3 , R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

  这项发明涉及式（I）的新型二氮杂环己烷衍生物，其中A、X、R3、R4、R5、R6、R8、R9、R10、R11、R12、R13、m和n的定义如描述和索赔中所述，以及其生理上可接受的盐。这些化合物是CCR-2受体、CCR-5受体和/或CCR-3受体的拮抗剂，可用作药物。
• Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
  申请人：WOCKHARDT RESEARCH CENTER

  公开号：US20020165227A1

  公开（公告）日：2002-11-07

  The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.

  本发明涉及光学纯的8-(取代哌啶基)-苯[i,j]喹啉，它们的异构体、衍生物、盐、伪多晶体、多晶体、前药和水合物，以及它们的制备方法和包含8-(取代哌啶基)-苯[i,j]喹啉、它们的异构体、衍生物、盐、伪多晶体、多晶体和水合物的药物组合物。这些化合物和组合物在治疗局部和全身感染方面具有强效活性，特别是对敏感和耐药革兰氏阳性菌感染、革兰氏阴性菌感染、分枝杆菌感染和医院感染病原体，特别是属于葡萄球菌、链球菌和肠球菌群的感染具有活性。通过将本发明的化合物用于人类和动物治疗上述感染引起的疾病和疾病的方法也被描述。
• Antibacterial chiral 8-(substituted piperidino)-benzo [i,j] quinolizines, processes, compositions and methods of treatment
  申请人：Wockhardt Limited

  公开号：US06608078B2

  公开（公告）日：2003-08-19

  The present invention relates to optically pure 8-(substituted piperidino)-benzo[i,j]quinolizines, their isomers, derivatives, salts, pseudopolymorphs, polymorphs prodrugs and hydrates thereof, to processes for their preparation, and to pharmaceutical compositions comprising 8-(substituted piperidino)-benzo[i,j]quinolizines their isomers, derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof. These compounds and compositions possess potent activity in treating local and systemic infections, particularly infections caused by sensitive and resistant Gram-positive organism infections, Gram-negative organism infections, mycobacterial infections and nosocomial pathogens, and particularly those belonging to the staphylococcus, streptococcus and enterococcus groups. Methods for treating the diseases and disorders arising from the foregoing infections in humans and animals are described by administering the compounds of the invention to said humans and animals.

  本发明涉及光学纯的8-（取代哌啶基）-苯并[i,j]喹啉，它们的异构体，衍生物，盐，伪多型，多型前药和水合物，以及它们的制备过程，以及包括8-（取代哌啶基）-苯并[i,j]喹啉，它们的异构体，衍生物，盐，伪多型，多型和水合物的制药组合物。这些化合物和组合物具有在治疗局部和全身感染方面的强效活性，特别是对于由敏感和耐药革兰氏阳性菌感染，革兰氏阴性菌感染，分枝杆菌感染和医院感染病原体引起的感染，特别是属于葡萄球菌，链球菌和肠球菌群的感染。通过将本发明的化合物用于人类和动物，可以描述用于治疗由上述感染引起的疾病和疾病的方法。
• Serotonergic benzofurans
  申请人：Briner Karin

  公开号：US06881733B1

  公开（公告）日：2005-04-19

  The present invention provides serotonergic benzofurans of Formula (I): where A, R, R 1 , R 2 , R 3 , and R 4 are as described in the specification.

  本发明提供了公式（I）的5-羟色胺苯并呋喃类化合物：其中A，R，R1，R2，R3和R4如规范中所述。
• Diazepan derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US07632829B2

  公开（公告）日：2009-12-15

  The invention is concerned with novel diazepan derivatives of formula (I) wherein A, X, R3, R4, R5, R6, R8, R9, R10, R11, R12, R13, m and n are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR-2 receptor, CCR-5 receptor and/or CCR-3 receptor and can be used as medicaments.

  这项发明涉及式(I)的新型二氮杂环衍生物，其中A、X、R3、R4、R5、R6、R8、R9、R10、R11、R12、R13、m和n如描述和权利要求中所定义，以及其生理上可接受的盐。这些化合物是CCR-2受体、CCR-5受体和/或CCR-3受体的拮抗剂，可以用作药物。